1. ALLA AKTIER
  2. NYHETER
  3. NEOLA MEDICAL

Neola Medical

Nyheter Neola Medical Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Neola Medical invites to presentation of the Q2-report 2025

Neola Medical AB (publ) invites to presentation of the Q2-report of 2025, Monday the 25th of August 2025 at 11:30 CET (11.30). The presentation will be held online as a webcast hosted by Finwire. The Q2-report will be published the same morning.

Neola Medical publishes the Q2-report in the morning the 25th of August 2025. We hereby invite investors, analysts, and journalists to a combined report presentation and webcast Monday the 25th of August 2025 at 11:30 CET (11.30). The report will be presented by CEO Hanna Sjöström and CFO David Folkesson.

Watch the presentation here: https://www.finwire.tv/webcast/neola-medical/q2-2025/ where you also can type in questions in advance and during the presentation that we will be answering live during the Q&A after the presentation.

For further questions after the presentation, contact CFO David Folkesson through below contact details.

The report and report presentation will be available at Neola Medical’s website:
https://www.neolamedical.com/investors/rapporter-och-finansiell-kalender/

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com
David Folkesson, CFO
e-mail: david.folkesson@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden’s longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical invites to presentation of the Q2-report 2025

Datum 2025-08-18, kl 07:00
Källa MFN
Bifogade filer
Neola Medical invites to presentation of the Q2-report 2025